| Autor: |
Salice M; a IBD unit, Department of Internal Medicine and Gastroenterology , University of Bologna , Bologna , Italy., Rizzello F; a IBD unit, Department of Internal Medicine and Gastroenterology , University of Bologna , Bologna , Italy., Calabrese C; a IBD unit, Department of Internal Medicine and Gastroenterology , University of Bologna , Bologna , Italy., Privitera Hrustemovic H; a IBD unit, Department of Internal Medicine and Gastroenterology , University of Bologna , Bologna , Italy., Gionchetti P; a IBD unit, Department of Internal Medicine and Gastroenterology , University of Bologna , Bologna , Italy. |
| Abstrakt: |
Introduction : Ulcerative colitis is an idiopathic, chronic inflammatory disease of the colonic mucosa. Its clinical course is unpredictable, marked by alternating periods of exacerbation and remission. Traditional oral corticosteroids are still the mainstay treatment for the induction of ulcerative colitis remission in patients failing or intolerant to aminosalicylates, but the risk of side effects and complications limits their usefulness. Based on these considerations, new steroids with low systemic bioavailability, such as Beclomethasone dipropionate and Budesonide, have been developed. Areas covered : We reviewed the current literature about the efficacy, safety and the role of budesonide MMX in the treatment of ulcerative colitis. The evidence reviewed in this article is a summation of relevant scientific publications, expert opinion statements, and current practice guidelines. Expert opinion : Budesonide MMX is a novel formulation that uses a Multi-Matrix System (MMX) technology to facilitate the release of high concentrations of active drug into the colon. Budesonide MMX at the dose of 9 mg/day for 8 weeks is effective and safe in inducing clinical and endoscopic remission in patients with mild to moderate UC, who had an inadequate response or were intolerant to either first line conventional therapy with topical and oral 5-aminosalicylic acid. |
